Hamps Bio IPO Details
The key details of Hamps Bio’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹6.22 Cr |
| Price Range | ₹51 |
| Retail Quota | 50% |
| QIB Quota | - |
| NII Quota | 50% |
| Employee Discount | -- |
| Listing at | BSE |
| Minimum Quantity | 2000 |
| Investment (cut-off price) | ₹102,000 |
| Pre IPO Promotor Holding | 100.00% |
| Post IPO Promotor Holding | 71.99% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Hamps Bio IPO Timelines
The IPO process for Hamps Bio includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
13/12/2024
Start Date17/12/2024
End Date19/12/2024
Refund Initiation19/12/2024
Credit of Shares to Demat Ac20/12/2024
Listing DateHamps Bio IPO Lot Size
The Hamps Bio IPO has a fixed lot size of 2,000 shares, at a fixed price band of ₹51 per share, requiring ₹102,000 per lot for retail investors. For HNI investors, the minimum application is 4,000 shares (2 lots) amounting to ₹204,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 2000 | ₹102,000 |
| Retail Maximum | 1 | 2000 | ₹102,000 |
| S-HNI Minimum | 2 | 4000 | ₹204,000 |
Hamps Bio IPO Subscription Status
The subscription status for Hamps Bio IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| -- | 758.27x | 1,342.04x | -- | 1,057.00x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹96.90 | ₹101.74 | ₹101.74 | ₹96.90 |
Hamps Bio IPO Company Financials
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹5.34 | ₹5.24 | ₹0.12 |
| FY 2023 | ₹5.58 | ₹5.23 | ₹0.36 |
| FY 2024 | ₹6.50 | ₹5.85 | ₹0.50 |
| FY 2025 (7 M) | ₹4.36 | ₹3.90 | ₹0.34 |
About Company
Hamps Bio Limited, incorporated in 2007, specializes in the marketing and distribution of pharmaceutical products such as tablets, syrups, capsules, injectables, oils, and nutritional supplements under the “Hamps” brand. Additionally, it operates a Freeze-Dried and Frozen Products (FDFP) division under the “FzyEzy” brand, offering items like strawberry, mango, and chikoo powders. The company’s diverse portfolio includes over 180 products, distributed through a network of 50+ distributors and major e-commerce platforms like Amazon, Flipkart, and Jio Mart. Its pharmaceutical products are available across 8 states and union territories, while its FDFP range reaches 6 countries and 22 states/UTs.
Hamps Bio employs a dual business model of B2B and B2C, with manufacturing capabilities in Gujarat for its FDFP products. Established as a strong player in the pharmaceutical and FMCG sectors, the company combines ethical marketing practices with innovation to cater to both domestic and international markets. As of October 2024, the company has a workforce of 78 employees and remains focused on expanding its reach and product portfolio.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2007 | Pharmaceuticals | Herrik Shah |
Know Before Investing
Hamps Bio IPO Strengths
- The company leverages seasoned leadership and extensive industry knowledge to drive innovation and sustained growth.
- A broad portfolio of pharmaceutical and FMCG products caters to diverse customer needs across multiple markets.
- A robust network of 50+ distributors and presence on major e-commerce platforms ensure wide market reach.
- The company maintains a loyal customer base across 6 countries, emphasizing trust and long-term partnerships.
Hamps Bio IPO Risks
- The company has demonstrated stagnant profit growth, with no significant increase over the past three years.
- Operating in a highly regulated industry, any failure to comply with regulations could adversely impact business operations.
- Revenue and profitability are susceptible to fluctuations in the pharmaceutical market, which can affect overall performance.
- Any disruptions in supply or increases in raw material costs could negatively impact production and profitability.
Swot Analysis for Hamps Bio IPO
Strengths
Diverse Product Range, Strong Brand Presence, Innovative Manufacturing
Weaknesses
Limited International Recognition, Dependence on Specific Markets, High Operational Costs
Opportunities
Growing Health Consciousness, Expansion Potential, E-commerce Growth
Threats
Intense Competition, Regulatory Compliance Risks, Economic Fluctuations
Company Details
Hamps Bio Limited
2900/112,
GIDC, Near Atul Limited,
Ankleshwar, Bharuch 393 002
Phone: +91 8000006663
Email: info@hampsbio.com
Website: http://www.hampsbio.com/
IPO Registar Details
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/ipo_status.html
FAQs
The key objectives of Hamps Bio IPO are:
- Purchase of plant & machinery for FMCG division
- Enhancing the visibility and awareness of the brand
- General corporate purposes
Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is the book-running lead managers for the Hamps Bio IPO.